Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Niraparib |
| Synonyms | |
| Therapy Description |
Zejula (niraparib) binds to and inhibits PARP, which may result in the accumulation of DNA damage and apoptosis of tumor cells (PMID: 23810788). Zejula (niraparib) is FDA-approved for use as maintenance therapy in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer in complete or partial response to first-line platinum-based chemotherapy, and as maintenance therapy in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer harboring deleterious or suspected deleterious germline BRCA mutations and in complete or partial response to platinum-based chemotherapy (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Niraparib | Zejula | MK4827 | PARP Inhibitor (Pan) 31 | Zejula (niraparib) binds to and inhibits PARP, which may result in the accumulation of DNA damage and apoptosis of tumor cells (PMID: 23810788). Zejula (niraparib) is FDA-approved for use as maintenance therapy in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer in complete or partial response to first-line platinum-based chemotherapy, and as maintenance therapy in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer harboring deleterious or suspected deleterious germline BRCA mutations and in complete or partial response to platinum-based chemotherapy (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| RAD51D K91Ifs*13 | ovarian cancer | sensitive | Niraparib | Preclinical - Cell culture | Actionable | In a preclinical study, Zejula (niraparib) inhibited viability of ovarian cancer cell lines expressing RAD51D K91Ifs*13 in culture (PMID: 38905575). | 38905575 |
| IDH1 R132C | cholangiocarcinoma | no benefit | Niraparib | Preclinical - Patient cell culture | Actionable | In a preclinical study, cholangiocarcinoma patient-derived xenograft (PDX) cell lines harboring IDH1 R132C were insensitive to Zejula (niraparib) in culture (PMID: 36374558). | 36374558 |
| ARID1B Q127_Q131del IDH1 R132L | cholangiocarcinoma | no benefit | Niraparib | Preclinical - Patient cell culture | Actionable | In a preclinical study, a cholangiocarcinoma patient-derived xenograft (PDX) cell line harboring IDH1 R132L and ARID1B Q127_Q131del was insensitive to Zejula (niraparib) in culture (PMID: 36374558). | 36374558 |
| IDH1 R132H | Advanced Solid Tumor | sensitive | Niraparib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells over expressing IDH1 R132H demonstrated increased sensitivity to Zejula (niraparib)-induced growth inhibition in culture (PMID: 28148839). | 28148839 |
| RAD51C R193W | ovarian carcinoma | resistant | Niraparib | Preclinical - Cell culture | Actionable | In a preclinical study, ovarian carcinoma cells expressing RAD51C R193W demonstrated resistance to Zejula (niraparib) in culture (PMID: 28588062). | 28588062 |
| RAD51C R193L | ovarian carcinoma | resistant | Niraparib | Preclinical - Cell culture | Actionable | In a preclinical study, ovarian carcinoma cells expressing RAD51C R193L demonstrated resistance to Zejula (niraparib) in culture (PMID: 28588062). | 28588062 |
| RAD51C H192_R193delinsGG | ovarian carcinoma | resistant | Niraparib | Preclinical - Cell culture | Actionable | In a preclinical study, ovarian carcinoma cells expressing RAD51C H192_R193delinsGG demonstrated resistance to Zejula (niraparib) in culture (PMID: 28588062). | 28588062 |
| PTEN negative | prostate cancer | not predictive | Niraparib | Phase I | Actionable | In a Phase I trial, negative PTEN IHC staining was not associated with response to Zejula (niraparib) treatment in patients with castration-resistant prostate cancer (PMID: 23810788; NCT00749502). | 23810788 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03925350 | Phase II | Niraparib | Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation | Unknown status | USA | 0 |
| NCT03651206 | Phase II | Paclitaxel + Pegylated liposomal doxorubicin + Topotecan Doxorubicin + Gemcitabine + Paclitaxel Niraparib Dostarlimab-gxly + Niraparib | Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib (ROCSAN) | Active, not recruiting | FRA | 0 |
| NCT02500901 | Phase I | Niraparib Enzalutamide | Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC) | Terminated | USA | 0 |
| NCT03891576 | Phase II | Niraparib | Newton Study (NEW Dosing mainTenance Therapy Ovarian caNcer) (Newton) | Active, not recruiting | ITA | DEU | 0 |
| NCT05961124 | Phase II | Niraparib | Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer | Recruiting | CAN | 0 |
| NCT05406700 | Phase I | Niraparib | Niraparib In Recurrent IDH 1/2 Gliomas | Recruiting | USA | 0 |
| NCT02655016 | Phase III | Niraparib | A Study of Niraparib Maintenance Treatment in Patients With HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy | Active, not recruiting | USA | SWE | POL | NOR | ITA | ISR | IRL | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BEL | 2 |
| NCT03359850 | Phase I | Niraparib | Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients | Completed | USA | 0 |
| NCT05174455 | Phase II | Niraparib | Niraparib for the Treatment of Leiomyosarcoma | Withdrawn | 0 | |
| NCT02925234 | Phase II | Crizotinib Sunitinib Niraparib Olaparib Lorlatinib Erdafitinib Talazoparib Dacomitinib Axitinib Panitumumab | The Drug Rediscovery Protocol (DRUP Trial) (DRUP) | Recruiting | NLD | 0 |
| NCT03601923 | Phase II | Niraparib | Niraparib in Patients With Pancreatic Cancer | Active, not recruiting | USA | 0 |
| NCT02854436 | Phase II | Niraparib | An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies | Completed | USA | SWE | NLD | ISR | GBR | FRA | ESP | DNK | CAN | BRA | BEL | AUS | 3 |
| NCT02354586 | Phase II | Niraparib | A Study of Niraparib in Patients With Ovarian Cancer Who Have Received at Least Three Previous Chemotherapy Regimens | Completed | USA | CAN | 0 |
| NCT05523440 | Phase II | Bevacizumab + Niraparib Niraparib | Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation | Recruiting | USA | 0 |
| NCT03308942 | Phase II | Niraparib Niraparib + Pembrolizumab Dostarlimab-gxly + Niraparib | Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants | Completed | USA | 0 |
| NCT04655183 | Phase Ib/II | Niraparib + VX-803 Niraparib | Study of M4344 in Combination With Niraparib | Withdrawn | 0 | |
| NCT05297864 | Phase II | Niraparib | PARP Inhibition for Gliomas (PI-4G or pi4g) | Terminated | USA | 0 |
| NCT04992013 | Phase II | Niraparib | Niraparib in Tumors Metastatic to the CNS | Recruiting | USA | 0 |
| NCT05615818 | Phase III | Niraparib ZW25 Binimetinib + Encorafenib Futibatinib Cisplatin + Gemcitabine Neratinib + Trastuzumab Ivosidenib | Personalized Medicine for Advanced Biliary Cancer Patients (SAFIR-ABC10) | Recruiting | GBR | FRA | BEL | 0 |
| NCT05442749 | Phase II | Niraparib | Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer (PARPi-PANC) | Withdrawn | FRA | 0 |
| NCT04030559 | Phase II | Niraparib | Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects | Recruiting | USA | 0 |
| NCT05455424 | Phase II | Niraparib | Niraparib Efficacy in Patient With Unresectable Mesothelioma (NERO) | Active, not recruiting | GBR | 0 |
| NCT05515575 | Phase II | Niraparib | A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA | Active, not recruiting | USA | 0 |
| NCT05672095 | Phase Ib/II | Niraparib | Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer | Not yet recruiting | USA | 0 |
| NCT04915755 | Phase III | Niraparib | Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease (ZEST) | Active, not recruiting | USA | ROU | POL | NOR | NLD | ITA | ISR | IRL | HUN | GBR | FRA | FIN | ESP | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 6 |
| NCT05076513 | Phase I | Niraparib | Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma | Recruiting | USA | 0 |
| NCT05169437 | Phase II | Niraparib | Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors (PAVO) | Terminated | USA | 0 |
| NCT04592237 | Phase II | Niraparib Cabazitaxel + Carboplatin + Cetrelimab Cetrelimab + Niraparib | Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer | Active, not recruiting | USA | 0 |
| NCT04080284 | Phase II | Niraparib | Trial of Maintenance With Niraparib- Uterine Serous Carcinoma | Recruiting | USA | 0 |
| NCT03088059 | Phase II | Niraparib Durvalumab + Monalizumab Methotrexate Carboplatin Rogaratinib Mitomycin C Docetaxel Afatinib Paclitaxel Durvalumab Monalizumab Palbociclib Bleomycin Gemcitabine Fluorouracil | Biomarker-based Study in R/M SCCHN (UPSTREAM) | Active, not recruiting | ITA | GBR | FRA | ESP | BEL | 0 |
| NCT04584255 | Phase II | Dostarlimab-gxly + Niraparib Niraparib | Niraparib + Dostarlimab In BRCA Mutated Breast Cancer | Recruiting | USA | 0 |
| NCT05990192 | Phase II | Niraparib | SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy (SOPRANO) | Recruiting | GBR | 0 |
| NCT03840967 | Phase II | Niraparib | A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma | Terminated | USA | 0 |
| NCT02354131 | Phase Ib/II | Niraparib Bevacizumab + Niraparib | Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer (AVANOVA) | Completed | USA | DNK | 0 |
| NCT03602859 | Phase III | Dostarlimab-gxly + Niraparib Niraparib | A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST) | Active, not recruiting | USA | ROU | POL | NOR | NLD | ITA | ISR | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BEL | 2 |
| NCT05238831 | Phase II | Vemurafenib Vinorelbine Palbociclib Irinotecan Alpelisib Capecitabine Atezolizumab Paclitaxel Entrectinib Cobimetinib Nab-paclitaxel Fulvestrant Carboplatin Olaparib Pertuzumab/trastuzumab/hyaluronidase-zzxf Niraparib Vismodegib Alectinib Letrozole Ado-trastuzumab emtansine Bevacizumab Eribulin Anastrozole | SMMART Adaptive Clinical Treatment (ACT) Trial | Withdrawn | 0 | |
| NCT03598270 | Phase III | Carboplatin + Gemcitabine Niraparib Carboplatin + Pegylated liposomal doxorubicin Atezolizumab + Carboplatin + Pegylated liposomal doxorubicin Atezolizumab + Carboplatin + Gemcitabine Atezolizumab + Carboplatin + Paclitaxel Carboplatin + Paclitaxel Atezolizumab + Niraparib | Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer (ANITA) | Completed | ITA | FRA | ESP | DEU | BEL | 0 |
| NCT05718323 | Phase II | Niraparib | Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC (RAISE) | Recruiting | ROU | ITA | FRA | ESP | CHE | 0 |
| NCT06077877 | Phase Ib/II | GSK4524101 + Niraparib GSK4524101 Niraparib | A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors | Recruiting | USA | CAN | 0 |
| NCT01905592 | Phase III | Niraparib | A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients (BRAVO) | Terminated | USA | POL | NLD | ITA | ISR | ISL | HUN | GRC | GBR | FRA | ESP | CAN | BEL | 1 |
| NCT06201234 | Phase II | Niraparib Elacestrant + Niraparib | Evaluating the Addition of Elacestrant (Oral SERD) to Niraparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer (ELEMENT) | Recruiting | DEU | 0 |
| NCT06412120 | FDA approved | Niraparib | Study Evaluating Safety, Tolerability, and Metabolism of Niraparib | Not yet recruiting | USA | 0 |
| NCT04037254 | Phase II | Niraparib | Niraparib With Standard Combination Radiation Therapy and Androgen Deprivation Therapy in Treating Patients With High Risk Prostate Cancer | Active, not recruiting | USA | CAN | 0 |
| NCT04221503 | Phase II | Niraparib | Niraparib/TTFields in GBM | Active, not recruiting | USA | 0 |
| NCT03207347 | Phase II | Niraparib | A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) | Completed | USA | 0 |
| NCT03644342 | Phase Ib/II | Niraparib | Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of the Cervix (NIVIX) | Terminated | USA | 0 |
| NCT06180356 | Phase II | Niraparib | Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression (ANALLISA) | Recruiting | ESP | 0 |
| NCT03945721 | Phase I | Niraparib | A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients (UNITY) | Active, not recruiting | USA | 0 |
| NCT04185831 | Phase II | Atezolizumab Niraparib Cobimetinib Everolimus | A MolEcularly Guided Anti-Cancer Drug Off-Label Trial (MEGALiT) | Active, not recruiting | SWE | 0 |
| NCT01847274 | Phase III | Niraparib | A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer | Completed | USA | SWE | POL | NOR | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUT | 0 |
| NCT04817956 | Phase II | Ceritinib Melphalan Cobimetinib + Vemurafenib Alectinib Pemigatinib Entrectinib Bortezomib Dostarlimab-gxly Atezolizumab Alpelisib Atezolizumab + Bevacizumab Olaparib Selpercatinib Capmatinib Dactinomycin Dabrafenib + Trametinib Vismodegib Niraparib Imatinib Pertuzumab/trastuzumab/hyaluronidase-zzxf | Improving Public Cancer Care by Implementing Precision Medicine in Norway (IMPRESS-N) | Recruiting | NOR | 0 |
| NCT04288687 | Phase II | Niraparib | A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects | Completed | USA | 0 |
| NCT03553004 | Phase II | Niraparib | Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 Trial | Active, not recruiting | USA | 0 |
| NCT03016338 | Phase II | Niraparib | Study of Niraparib in Recurrent Endometrial Cancer | Active, not recruiting | CAN | 0 |
| NCT03329001 | Phase I | Niraparib | Crossover Study to Assess the Relative Bioavailability of Niraparib Tablet Compared to Niraparib Capsule | Completed | USA | 0 |
| NCT04341181 | Phase II | Atezolizumab Niraparib Erlotinib Axitinib Cobimetinib + Vemurafenib Avelumab Pertuzumab + Trastuzumab Vismodegib Alectinib Ado-trastuzumab emtansine | ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling (ProTarget) | Recruiting | DNK | 0 |
| NCT04861181 | FDA approved | Niraparib | NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients. (NIRAPK) | Recruiting | FRA | 0 |
| NCT04240106 | Phase II | Niraparib | Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN) | Completed | ESP | 0 |
| NCT04641247 | Phase II | Niraparib | A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study | Active, not recruiting | USA | ITA | ISR | FRA | ESP | DNK | CAN | AUT | 0 |
| NCT06388733 | Phase III | Niraparib Temozolomide | A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma | Recruiting | USA | 0 |
| NCT03329937 | Phase I | Niraparib | Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment | Completed | USA | 0 |
CKB BOOST